FarhadKhimaniMD

Oncology • Tampa, FL

Physician

Join to view full profile

Dr. Khimani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Khimani's full profile

Already have an account?

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Phone+1 813-745-6871

Summary

Dr. Farhad Khimani is a Blood & Marrow Transplant and Cellular therapy Physician in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Aga Khan University Medical College and has been in practice for12 years. He is experienced in bone marrow transplantation & CAR-T cell therapy and sees patient with acute myeloid leukemia, lymphoma, myeloproliferative neoplasms, and myelodysplastic syndromes for the same. He has more than 40 publications and over 300 citings.

Clinical Expertise

Bone marrow transplantation, Acute myeloid leukemia, Lymphoma, Myeloproliferative neoplasms, Myelodysplastic syndromes , CAR-T cell therapy

Education & Training

H. Lee Moffitt Cancer CenterAdvanced Fellowship, Blood and Marrow Transplant, 2014 - 2015
West Virginia UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
West Virginia UniversityResidency, Internal Medicine, 2008 - 2011
Aga Khan Medical CollegeClass of 2005

Certifications & Licensure

FL State Medical License 2015 - 2025
WV State Medical License 2011 - 2016
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX Start of enrollment: 2012 Feb 01
Terminated
Phase 2
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Start of enrollment: 2016 Dec 01
Completed
Phase 2
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2019 Feb 15
Completed
Phase 1
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML Start of enrollment: 2021 Jan 14
Active, not recruiting
Phase 1, Phase 2
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Start of enrollment: 2023 Dec 08
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

8 citations
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Dae Hyun Lee, Abhishek Kumar, Turab Mohammed, Lauren C Peres, Melissa Alsina
Blood Advances. 2023-08-22
43 citations
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.
Jennifer M Logue, Lauren C Peres, Hamza Hashmi, Christelle M Colin-Leitzinger, Alexandria M Shrewsbury
Blood Advances. 2022-12-27
161 citations
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.
Jennifer M. Logue, Elisa Zucchetti, Christina A Bachmeier, Gabriel S Krivenko, Victoria Larson
Haematologica. 2020-04-23